Chronic pulmonary obstructive disease (COPD) is the fourth leading cause of death worldwide, however, the pathogenic factors and mechanisms are not fully understood. Pulmonary emphysema is one of the major components of COPD and is thought to result from oxidative stress, chronic inflammation, protease-antiprotease imbalance and lung epithelial (LE) cell apoptosis. In our previous studies, COPD patients were noted to have higher levels of placenta growth factor (PlGF) in serum and bronchoalveolar lavage fluid than controls. In addition, transgenic mice overexpressing PlGF developed pulmonary emphysema and exposure to PlGF in LE cells induced apoptosis. Furthermore, intratracheal instillation of porcine pancreatic elastase (PPE) on to PlGF wild type mice induced emphysema, but not in PlGF knockout mice. Therefore, we hypothesized that PPE generates pulmonary emphysema through the upregulation of PlGF expression in LE cells. The elevation of PlGF then leads to LE cell apoptosis. In the present study, we investigated whether PPE induces PlGF expression, whether PlGF induces apoptosis and whether the downstream mechanisms of PlGF are related to LE cell apoptosis. We found that PPE increased PlGF secretion and expression both in vivo and in vitro. Moreover, PlGF-induced LE cell apoptosis and PPE-induced emphysema in the mice were mediated by c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38 MAPK) pathways. Given these findings, we suggest that the increase in PlGF and PlGF-induced JNK and p38 MAPK pathways contribute to PPE-induced LE cell apoptosis and emphysema. Regulatory control of PlGF and agents against its downstream signals may be potential therapeutic targets for COPD.
Subject Category: Experimental Medicine
Chronic pulmonary obstructive disease (COPD) is the fourth leading cause of death worldwide with high mortality and morbidity rates even under advanced medical care. 1 Emphysema is a major component of COPD and is characterized by destruction and enlargement of the alveolar region through chronic inflammation, oxidative stress and protease-antiprotease imbalance. 2, 3 However, the factors and pathogenic mechanisms that cause COPD are not fully understood. 4 Apoptosis of lung epithelial (LE) cells is one of the potential factors involved in the pathogenesis of COPD. 5 Tsao et al. 6 demonstrated that exogenous placenta growth factor (PlGF) induced LE cell apoptosis and inhibited cellular proliferation, and that the transgenic mice with over-expressed PlGF developed emphysema phenotype, suggesting that PlGF has an important role in the pathogenesis of emphysema.
PlGF belongs to a family of vascular endothelial growth factors (VEGF) and the major biological function of PlGF is promoting angiogenesis through VEGF receptor-1 (VEGFR-1) signaling. 7, 8 PlGF expresses in the placenta, heart, lung, thyroid, brain and skeletal muscles. 9 Increasing evidence suggest that PlGF expressed in LE cells may contribute to the progression of COPD. Cheng et al. 10 reported that patients with COPD had higher levels of PlGF in serum and bronchoalveolar lavage (BAL) fluid, and that the level of PlGF was inversely related to lung function. Moreover, cigarette smoke, a major factor related to COPD, has been found to increase PlGF expression in rat lungs. 11 Furthermore, ablation of PlGF has been found to protect mice from porcine pancreatic elastase (PPE)-induced emphysema. 12 However, the detailed mechanisms underlining PlGF-induced LE cell apoptosis and the pathogenesis of emphysema remain to be elucidated.
PPE is a protease that can induce protease-antiprotease imbalance and has been applied in an animal model of emphysema and COPD. 13 Previous studies have demonstrated that leukocyte elastase increases lung and intestinal epithelial cells apoptosis. 14, 15 Neutrophil elastase (NE) has been shown to increase the expression and secretion of elafin in type II alveolar epithelial cells. 16 Moreover, NE has also been shown to increase the expression of MUC4 and MUC5AC 17, 18 and promote the secretion of mucin and expression of interleukin-8 (IL-8) in human bronchial epithelial cells. 19, 20 Other than LE cells, NE has also been shown to upregulate cathepsin B and matrix matelloprotease-2 (MMP-2) in macrophages. 21 To date, the mechanisms by which elastase induces LE cell apoptosis have not been established. In this study, we hypothesized that PPE generates LE cell apoptosis and pulmonary emphysema through the expression of PlGF and PlGF-mediated downstream signaling.
We found that PPE increased PlGF mRNA and protein expressions in vivo and in vitro. PPE stimulates PlGF promoter activity by early growth response-1 (Egr-1) and Egr-1 response element. Moreover, PlGF induced LE cell apoptosis in a dosedependent manner, and chronic treatment of PlGF increased LE cell apoptosis. Furthermore, PlGF activated c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) pathways, both of which were involved in PlGF-induced LE cell apoptosis and PPE-induced pulmonary emphysema in mice. These novel findings may provide possible therapeutic strategies for emphysema and COPD.
Results

PPE treatment increased PlGF expression and secretion
in LE cells. Previous study indicated 100 mU/ml NE increases elafin gene expression in A549 cells 16 and PlGF is majorly secreted by alveolar type II epithelial cells. 6, 22 Therefore, the mouse LE cells, mouse alveolar type II epithelial cells (MLE-15), were treated with 0-60 mU/ml PPE for 24 h to test whether PPE could induce PlGF expression. The secretion of PlGF into the medium was promoted by 60 mU/ml PPE treatment ( Figure 1a ). In MLE-15 cells, the mouse PlGF promoter region (2.5 kb)-driven luciferase activity indicated that 60 mU/ml PPE increased the mouse PlGF promoter activity by about threefold (Figure 1b ). The results of reverse transcriptional (RT)-PCR and western blot demonstrated that 60 mU/ml PPE upregulated the expressions of PlGF mRNA and protein in the MLE-15 cells (Figures 1c and  d) . To study the transcriptional regulatory mechanism of PPE on PlGF expression, we analyzed the sequence of human PlGF promoter region and identified a speculated Egr-1 response element (CCCGCCCC) within 100 bp from transcriptional start site. 23, 24 Western blot demonstrated that 60 mU/ml PPE transiently increased the expressions of Egr-1 in MLE-15 cells ( Figure 1e ). The data of chromatin immunoprecipitation assay showed that the exposure to 60 mU/ml PPE for 1 h would promote the association of Egr-1 protein and PlGF promoter region ( Figure 1f ). These findings confirmed that PPE increased PlGF expression and secretion in mouse LE cells.
Exogenous PlGF induced LE cell apoptosis. Previous study indicated that 100 ng/ml PlGF induced MLE-15 cell apoptosis. 6 In this study, MLE-15 cells were treated with 0-100 ng/ml mouse recombinant PlGF for 24 h. Exogenous PlGF dose-dependently increased the level of apoptosis in the MLE-15 cells according to the results of the caspase-3 activity assay (Figure 2a ), trypan blue inclusion analysis ( Figure 2b ), flow cytometric assay ( Figure 2c ) and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay (Figure 2d ). Because the level of cells with trypan blue stain is similar to FITC-positive cell and a few annexin V-positive cells in cytomertic assay, PlGF majorly induced apoptotic cellular death rather than necrotic cellular death in LE cells. In addition, S cells were treated with 0-100 ng/ml human recombinant PlGF for 24 h. The results of the caspase-3 activity assay demonstrated that PlGF also increased human LE cell apoptosis in a dosedependent manner (Figure 2e ). Our previous study indicated co-treatment of 50 pg/ml PlGF, 200 pg/ml interleukin-8 (IL-8) and 200 pg/ml tumor necrosis factor-a (TNFa) for 14 days induced S-cell apoptosis. 10 To mimic the chronic damage conditions in COPD, the S cells were treated with 800 pg/ml human recombinant PlGF for 14 days. The dose of PPE was dependent on PPE-induced PlGF secretion in S cells (data not shown). Chronic treatment with 800 pg/ml PlGF resulted in a similar apoptotic level as Figure 2e Figure 2S ). Moreover, PPE-treated mice displayed more phosphorylated JNK and p38 MAPK levels than the control mice (arrowheads in Figure 5a ). In addition, the BAL fluid of the PPE-treated mice had higher PlGF levels than that of the control mice ( Figure 5b ). These results demonstrated that PPE instillation increase PlGF expression, activation of JNK and p38 MAPK, and PlGF secretion in the pulmonary cells of mice. Figure 3S ). TUNEL assay indicated apoptotic cells in pulmonary tissue (Figure 6a ), and the PPE-treated mice had a higher level of pulmonary apoptosis than the control mice ( Figure 6c ). Moreover, the PPEtreated mice had the emphysema phenotype with enlargement of the alveolar space ( Figure 6b ) as evaluated by 
Discussion
Several studies have reported that elastase, a serine protease, induces epithelial cell apoptosis. Leukocyte elastase damages the intestinal epithelial cells via loss of mitochondrial integrity, and decreasing Akt and increasing JNK signaling. 15 Moreover, the leukocyte elastase-induced LE cell apoptosis has been shown to be mediated by protease-activated receptor-1, and retinoic acid has been shown to abrogate leukocyte elastaseinduced LE cell apoptosis. 14 The pathogenesis of COPD is chronic airway inflammation due to neutrophil and macrophage recruitment 26, 27 followed by the secretion of NE and matrix metalloprotease. A protease-antiprotease imbalance may modify gene expression profiles in LE cells to overcome the extracellular stimuli. Previous studies have indicated that NE increases the expressions of elafin, MUC4 and MUC5AC, and the secretion of elafin and mucin in LE cells. [16] [17] [18] [19] In bronchial epithelial cells, NE has also been shown to upregulate the expression of IL-8 through Toll-like receptor-4 signaling. 20 Using mouse LE cells, PPE was shown to induce the expression of PlGF mRNA and protein in a dose-dependent manner in the present study. According to previous studies, the expression of PlGF in lung tissue was upregulated by hypoxic stimuli and lung stretch 23,28 and 1.5-kb upstream promoter region was sufficient for hypoxia induction. 23 We also validated that PPE-induced PlGF mRNA expression was mediated by the interaction of Egr-1 protein and Egr-1 response element in PlGF promoter.
COPD is a major cause of death worldwide. 29 The levels of airway inflammation and obstruction may insidiously progress, and the early diagnosis and treatment is usually difficult due to the lack of pathognomonic clinical symptoms. Effective biomarker for early detection and therapeutic agents for COPD remain elusive. 30, 31 Cigarette smoke, the major factor related to COPD, has been proven to increase PlGF expression. 11 In this study, we demonstrated that PPEinduced protease-antiprotease imbalance, the pathogenic mechanism for COPD, increased the expression of PlGF. In future studies, we will explore the mechanisms, such as DNA methylation, small nucleotide polymorphism and micro-RNA, associated with the regulation of PlGF expression. We hypothesize that PlGF is a prognostic or predictive biomarker for COPD.
Kinase inhibitors for JNK and p38 MAPK have been used as experimental therapeutic strategies in patients with COPD. 32, 33 In the pathogenic processes of COPD, p38 MAPK signaling has been found to have roles in the activation of inflammation cascade and infiltration of immunocytes in vivo and in vitro. 34 One clinical trial demonstrated a better clinical efficacy in COPD patients receiving p38 MAPK inhibitor therapy. 35 Our results also demonstrated additional beneficial effects of using JNK and p38 MAPK inhibitors in COPD therapy. First, ablation of JNK and p38 MAPK signaling prevented the PlGF-induced LE cells apoptosis, which is a potential mechanism for COPD. Second, inhibition of JNK and p38 MAPK activity attenuated Protein extraction and immunoblot analysis. Treated or untreated MLE-15 and S cells were lysed using RIPA lysis buffer (Genestar, Taipei, Taiwan), which contained 1% NP-40, 0.1% SDS, 150 mM sodium chloride, 0.5% sodium deoxycholate and 50 mM Tris with a protease inhibitor cocktail (Bionovas, Toronto, Canada) and PhosSTOP (Roche, Basilea, Switzerland). Cellular lysates were centrifuged at 12 000 r.p.m. for 5 min and the resulting supernatant was collected. The extracted protein was quantified by protein assay. Equal amounts of protein were separated using 10% SDS-polyacrylamide gel electrophoresis and transferred to Immobilon-P membranes (Millipore, MA, USA). After blocking with 5% skimmed milk, the membranes were incubated with various primary antibodies and then incubated with the corresponding secondary antibodies. The protein bands were detected using an Immobilon Western Chemiluminescent HRP Substrate (Millipore, Billerica, MA, USA) and quantified by ImageQuant 5.2 software (Healthcare Bio-Sciences, Philadelphia, PA, USA).
Chromatin immunoprecipitation (ChIP). Genomic DNA fragment from treated-or untreated-MLE-15 cells were prepared by the EZ-Zyme Chromatin Prep Kit (Millipore) and analyzed by the Chromatin immunoprecipitation (ChIP) Assay Kit (Millipore) to evaluate the associated level of Egr-1 and PlGF promoter region. The antibody of Egr-1 was used for immunoprecipitation and the primer set (5 0 -CAG AGG TCA CTT AAG TAC CCA GCC ATC T-3 0 and 5 0 -ATA AGC TTT GCA GTC TGC CTG AGC ATC C-3 0 ) were used for amplify of mouse PlGF promoter according to the manufacturer's instructions. Trypan blue inclusion assay. Treated or untreated MLE-15 cells were treated with 0-100 ng/ml PlGF for 24 h then stained with trypan blue (1 : 1 in volume), and the cells that stained blue were counted using a hemacytometer counting chamber (Invitrogen). H&E stain. Paraffin was removed from paraffin-embedded tissue sections from the mice by xylene, dehydrated by ethanol and rehydrated by PBS. The sections stained with hematoxylin and eosin were then analyzed by a Leica DM 4000B microscope (Leica).
Caspase
PPE-induced emphysema. The intratracheal instillation of PPE into the C57BL/6 WT mice was performed as described previously. 11 In brief, eight-weekold mice were instilled intratracheally with saline (CON), 100 mU/ml PPE (PPE), 100 mU/ml PPE with 50 mg/kg JNK inhibitor SP600125 (PPE SP), 50 mg/kg p38 MAPK inhibitor SB 203580 (PPE SB), 3 mg/kg scramble siRNA (PPE Sc-si) and 3 mg/kg mouse PlGF siRNA (PPE Pl-si) weekly for one month. The dose of siRNA instillation was according to previous study. 36 There were five mice in each group. Lung tissue and BAL fluid collection were performed as described previously. 10 Statistical analysis. The results are presented as mean±S.E.M. from five independent repeats and animals. The Mann-Whitney test was used to compare two independent groups. Kruskal-Wallis followed by Bonferroni post-hoc analysis was used for multiple testing. Statistical analyses were performed using SPSS version 8.0 (SPSS Inc., Chicago, IL, USA). A P-value o0.05 was considered statistically significant.
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